In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Kos, Triad Pharmaceuticals in cholesterol drug deal

Executive Summary

Specialty drug company Kos Pharmaceuticals (cardiovascular, respiratory, and metabolic diseases) will invest $4mm in Triad Pharmaceuticals, a Boston-area company discovering and developing therapies for cholesterol disorders, diabetes, and cancer. In return, Triad will carry out research for Kos to find compounds that regulate HDL (high-density lipoproteins, or the "good" cholesterol).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies